PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ — Telik,
Inc. (Nasdaq: TELK) today announced the publication of a review
in the journal, Cell Death and Differentiation: Glutathione
transferases as mediators of signaling pathways involved in cell
proliferation and cell death;
http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html.
This review describes recent advances in the understanding of
the important role that the enzyme GSTP1-1 plays in the progression
of cancer and other diseases associated with increased cell
proliferation. Telintra®, Telik’s investigational drug
candidate inhibitor of GSTP1-1, has recently been reported to show
positive results in a Phase 2 trial in patients with MDS, a disease
characterized by disordered cell proliferation and differentiation.
Reprints of the publication are available from Telik.
Background on MDS
The myelodysplastic syndromes (MDS) are a heterogeneous group of
clonal hematopoietic stem cell disorders characterized by
ineffective hematopoiesis (blood cell production) involving one or
more cell lineages (red blood cells, white blood cells or
platelets) and a variable risk of transformation to acute myeloid
leukemia (AML). MDS becomes more common with age. It is
estimated that MDS affects approximately 300,000 people worldwide.
According to the American Cancer Society, 10,000–20,000
new cases of MDS are diagnosed each year in
SOURCE
